This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Genus Pharmaceuticals

Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN
Telephone: +44 (0)1635 568 400
Fax: +44 (0)1635 568 401
Medical Information Direct Line: +44 (0)870 851 0207
Medical Information e-mail: genus@medinformation.co.uk
Customer Care direct line: +44 (0)1635 568 445
Medical Information Fax: +44 (0)1793 710 387

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 11/09/2008
SPC Hirudoid Cream


Go to top of the page
1. Name of the medicinal product

Hirudoid Cream


Go to top of the page
2. Qualitative and quantitative composition

Heparinoid 0.3% w/w (Equivalent to 25 000 Units per 100 g cream).


Go to top of the page
3. Pharmaceutical form

Topical cream.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Hirudoid is indicated for the treatment of superficial thrombophlebitis and the soothing relief of superficial bruising and haematoma.


Go to top of the page
4.2 Posology and method of administration

Adults, the elderly and children over 5 years of age:

Two to six inches (5-15 cm) to be applied up to four times daily to the affected area and gently massaged into the skin.


Go to top of the page
4.3 Contraindications

Not to be used on large areas of skin, broken skin, sensitive areas of skin or mucous membranes. Not to be used in individuals with a known sensitivity to any active or inactive component of the formulation. Not to be used in children under 5 years of age.


Go to top of the page
4.4 Special warnings and precautions for use

For external use only. If symptoms persist or worsen, seek medical advice. Do not exceed the stated dose.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6. Pregnancy and lactation

There is no evidence to suggest that Hirudoid should not be used during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

None known.


Go to top of the page
4.9 Overdose

In the absence of any reports of the accidental ingestion of Hirudoid, no specific advice is available. General supportive measures may be appropriate.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Heparinoid is recognised as having: a weak inhibitory effect on PGE2 synthesis and an indirect effect on LTB4 production (based on in vitro studies), anti-coagulant activity (as a heparinoid), thrombolytic activity (through potentiation of urokinase activity), anti-exudatory activity (through inhibition of hyaluronidase).


Go to top of the page
5.2 Pharmacokinetic properties

Radiochemical studies of absorption following cutaneous application of heparinoid (mucopolysaccharide polysulphate) have shown that between 0.3 and 4% of the mucopolysaccharide administered is absorbed by various tissues (other than the treated area) within the first 8 hours. Typically between 1.7% and 4.6% will be absorbed within 2 to 4 days. Animal studies have also shown that mucopolysaccharide is bound intracellularly within the subcutis. Peak serum concentrations following cutaneous application are below the threshold of physiological relevance for coagulation. Mucopolysaccharide is excreted in the urine partly unchanged and partly as depolymerized, shorter chain length molecules.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Anhydrous eucerine

Emulsifying cetostearyl alcohol type A

Glycerol

Isopropyl alcohol

Methyl parahydroxybenzoate (E218)

Myristyl alcohol, potassium hydroxide

Propyl parahydroxybenzoate (E216)

Purified water

Stearic acid

Thymol


Go to top of the page
6.2 Incompatibilities

None.


Go to top of the page
6.3 Shelf life

5 years.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.


Go to top of the page
6.5 Nature and contents of container

Lacquered aluminium tubes 14, 40, 50 g.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. Marketing authorisation holder

Genus Pharmaceuticals Limited

T/A Genus Pharmaceuticals

Park View House

65 London Road

Newbury

Berkshire RG14 1JN

United Kingdom


Go to top of the page
8. Marketing authorisation number(s)

PL 06831/0175


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

02 February 2006


Go to top of the page
10. Date of revision of the text

23 July 2008



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/5001/SPC/


Active Ingredients/Generics